Immunocore Holdings plc (IMCR): Total Liabilities
$686.24M
As of 2025-12-31
$699.62M
As of 2026-06-30
+54.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $686.24M | +5.8% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $648.79M | +184.4% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $228.16M | +21.5% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $187.86M | n/a | 2024-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
Compare IMCR, KRYS, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗